FDA OKs Ritlecitinib for Ages 12 and Up for Alopecia Areata FDA OKs Ritlecitinib for Ages 12 and Up for Alopecia Areata
The approval follows the approval of the JAK inhibitor baricitinib for alopecia areata in adults in 2022.News Alerts
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Dermatology News Alert Source Type: news